Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

TY - JOUR

T1 - Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

AU - Snowden, John A

AU - Sánchez-Ortega, Isabel

AU - Corbacioglu, Selim

AU - Basak, Grzegorz W

AU - Chabannon, Christian

AU - de la Camara, Rafael

AU - Dolstra, Harry

AU - Duarte, Rafael F

AU - Glass, Bertram

AU - Greco, Raffaella

AU - Lankester, Arjan C

AU - Mohty, Mohamad

AU - Neven, Bénédicte

AU - de Latour, Régis Peffault

AU - Pedrazzoli, Paolo

AU - Peric, Zinaida

AU - Yakoub-Agha, Ibrahim

AU - Sureda, Anna

AU - Kröger, Nicolaus

AU - European Society for Blood and Marrow Transplantation (EBMT)

PY - 2022/8

Y1 - 2022/8

N2 - For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the eighth special EBMT report on the indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered in conjunction with the risk of the disease, risk of HCT procedure and non-transplant strategies, including evolving cellular therapies. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE accreditation standards to maintain quality in clinical and laboratory components of practice, including benchmarking of survival outcomes. Since the last edition, the COVID-19 pandemic has affected clinical decision making and activity across indications. Although the full impact of the pandemic is yet to be determined, we recommend that decision making across indications is delivered with ongoing reference to EBMT and national COVID-19 guidance, in accordance with current local conditions.

AB - For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the eighth special EBMT report on the indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered in conjunction with the risk of the disease, risk of HCT procedure and non-transplant strategies, including evolving cellular therapies. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE accreditation standards to maintain quality in clinical and laboratory components of practice, including benchmarking of survival outcomes. Since the last edition, the COVID-19 pandemic has affected clinical decision making and activity across indications. Although the full impact of the pandemic is yet to be determined, we recommend that decision making across indications is delivered with ongoing reference to EBMT and national COVID-19 guidance, in accordance with current local conditions.

KW - Europe

KW - Hematologic Diseases/therapy

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Immune System Diseases/therapy

KW - Neoplasms/therapy

U2 - 10.1038/s41409-022-01691-w

DO - 10.1038/s41409-022-01691-w

M3 - SCORING: Journal article

C2 - 35589997

VL - 57

SP - 1217

EP - 1239

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 8

ER -